Sakib Burza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1382871/publications.pdf

Version: 2024-02-01

430874 345221 2,281 39 18 36 h-index citations g-index papers 3190 43 43 43 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. Clinical Infectious Diseases, 2022, 75, 1423-1432.	5.8	16
2	Behavioural interventions to address rational use of antibiotics in outpatient settings of lowâ€income and lowerâ€middleâ€income countries. Tropical Medicine and International Health, 2021, 26, 504-517.	2.3	11
3	Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Leishmania Transmission at the Village Level in Bihar, India. Frontiers in Cellular and Infection Microbiology, 2021, 11, 604117.	3.9	15
4	Evaluation of qPCR on blood and skin microbiopsies, peripheral blood buffy coat smear, and urine antigen ELISA for diagnosis and test of cure for visceral leishmaniasis in HIV-coinfected patients in India: a prospective cohort study. BMJ Open, 2021, 11, e042519.	1.9	2
5	India's National Action Plan on Antimicrobial Resistance: a critical perspective. Journal of Global Antimicrobial Resistance, 2021, 27, 236-238.	2.2	15
6	Lived experiences of palliative care among people living with HIV/AIDS: a qualitative study from Bihar, India. BMJ Open, 2020, 10, e036179.	1.9	1
7	Quality of life perceptions amongst patients co-infected with Visceral Leishmaniasis and HIV: AÂqualitative study from Bihar, India. PLoS ONE, 2020, 15, e0227911.	2.5	7
8	Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. PLoS Neglected Tropical Diseases, 2020, 14, e0007995.	3.0	31
9	Standardized Protocol Items Recommendations for Observational Studies (SPIROS) for Observational Study Protocol Reporting Guidelines: Protocol for a Delphi Study. JMIR Research Protocols, 2020, 9, e17864.	1.0	9
10	"lt's just a fever― Gender based barriers to care-seeking for visceral leishmaniasis in highly endemic districts of India: A qualitative study. PLoS Neglected Tropical Diseases, 2019, 13, e0007457.	3.0	5
11	Malnutrition in Chakradharpur, Jharkhand: an anthropological study of perceptions and care practices from India. BMC Nutrition, 2019, 5, 35.	1.6	6
12	"Without antibiotics, I cannot treat― A qualitative study of antibiotic use in Paschim Bardhaman district of West Bengal, India. PLoS ONE, 2019, 14, e0219002.	2.5	26
13	Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India. PLoS Neglected Tropical Diseases, 2019, 13, e0007726.	3.0	12
14	Knowledge, attitudes, and practices related to antibiotic use in Paschim Bardhaman District: A survey of healthcare providers in West Bengal, India. PLoS ONE, 2019, 14, e0217818.	2.5	44
15	Leishmaniasis – Authors' reply. Lancet, The, 2019, 393, 872-873.	13.7	16
16	Reply to Shamim Islam. Clinical Infectious Diseases, 2019, 69, 190-190.	5.8	0
17	Refused and referred-persistent stigma and discrimination against people living with HIV/AIDS in Bihar: a qualitative study from India. BMJ Open, 2019, 9, e033790.	1.9	16
18	Control and Public Health Aspects. , 2018, , 227-245.		1

#	Article	IF	CITATIONS
19	Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post–Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh. Clinical Infectious Diseases, 2018, 67, 667-675.	5.8	25
20	Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS Neglected Tropical Diseases, 2018, 12, e0006830.	3.0	17
21	New insights into leishmaniasis in the immunosuppressed. PLoS Neglected Tropical Diseases, 2018, 12, e0006375.	3.0	75
22	Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?. Open Forum Infectious Diseases, 2018, 5, ofy059.	0.9	10
23	Leishmaniasis. Lancet, The, 2018, 392, 951-970.	13.7	1,264
24	Combination treatment for visceral leishmaniasis patients co-infected with human immunodeficiency virus in India. International Journal of Infectious Diseases, 2016, 45, 55.	3.3	0
25	Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. Parasites and Vectors, 2016, 9, 25.	2.5	55
26	Seasonal effect and long-term nutritional status following exit from a Community-Based Management of Severe Acute Malnutrition program in Bihar, India. European Journal of Clinical Nutrition, 2016, 70, 437-444.	2.9	29
27	Health-seeking behaviour and community perceptions of childhood undernutrition and a community management of acute malnutrition (CMAM) programme in rural Bihar, India: a qualitative study. Public Health Nutrition, 2015, 18, 3234-3243.	2.2	34
28	Reply to R Dasgupta et al American Journal of Clinical Nutrition, 2015, 102, 1298-1299.	4.7	0
29	Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clinical Infectious Diseases, 2015, 61, 1255-1262.	5 . 8	53
30	Community-based management of severe acute malnutrition in India: new evidence from Bihar. American Journal of Clinical Nutrition, 2015, 101, 847-859.	4.7	67
31	Diagnosis of neglected tropical diseases among patients with persistent digestive disorders (diarrhoea and/or abdominal pain ≥14Âdays): a multi-country, prospective, non-experimental case–control study. BMC Infectious Diseases, 2015, 15, 338.	2.9	16
32	HIV and Visceral Leishmaniasis Coinfection in Bihar, India: An Underrecognized and Underdiagnosed Threat Against Elimination. Clinical Infectious Diseases, 2014, 59, 552-555.	5.8	51
33	Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2603.	3.0	52
34	Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2536.	3.0	49
35	Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2611.	3.0	32
36	Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome). PLoS Neglected Tropical Diseases, 2014, 8, e3053.	3.0	51

SAKIB BURZA

#	Article	IF	CITATIONS
37	Multiple relapses of visceral leishmaniasis in a patient with HIV in India: A treatment challenge. International Journal of Infectious Diseases, 2014, 25, 204-206.	3.3	10
38	One-Year Follow-up of Immunocompetent Male Patients Treated With Miltefosine For Primary Visceral Leishmaniasis in Bihar, India. Clinical Infectious Diseases, 2013, 57, 1363-1364.	5.8	25
39	Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opinion on Emerging Drugs, 2012, 17, 493-510.	2.4	130